ACAD Sep 2024 10.000 call
| Previous close | 6.65 |
| Open | N/A |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 10.00 |
| Expiry date | 2024-09-20 |
| Day's range | 6.65 - 6.65 |
| Contract range | N/A |
| Volume | |
| Open interest | 5 |
Business WireAcadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting
SAN DIEGO, June 18, 2024--Acadia Pharmaceuticals, Inc. (Nasdaq: ACAD) today announced that interim data from the open-label real-world LOTUS™ study will be presented at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting, being held this week in Westminster, Colorado. LOTUS is an ongoing, caregiver-reported study evaluating the efficacy and tolerability outcomes in patients with Rett syndrome treated with DAYBUE™ (trofinetide).
Simply Wall St.It's Probably Less Likely That ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Will See A Huge Pay Rise This Year
Key Insights ACADIA Pharmaceuticals' Annual General Meeting to take place on 29th of May Total pay for CEO Steve Davis...
Business WireAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, May 17, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on May 15, 2024, the Compensation Committee of Acadia’s Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock options to purchase 57,252 shares of common stock and 33,675 restricted stock units ("RSUs") to twenty-two new employees under Acadia’s 2023 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ emplo
